According to this scenario, the decrease in cytokine release after LPS inflammatory stimulus and the polarization of microglial cells towards an anti-inflammatory phenotype, as confirmed by the induction of IL-10 and arginase-1, following Milmed addition, leads to the assertion that Milmed supplementation offers a promising treatment for pathologies arising from neuro-inflammation, such as depression, Parkinsonism and AD. Here, IL10 is linked to depressive disorder.